New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NVS;MOS;SCCO;ADM;IP From The Last 14 Days
Check below for free stories on NVS;MOS;SCCO;ADM;IP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
April 7, 2014
05:32 EDTNVSNovartis Bexsero vaccine receives FDA Breakthrough Therapy designation
Novartis announced that Bexsero, Meningococcal Group B Vaccine, has received a Breakthrough Therapy designation from the FDA. Bexsero is already approved in Europe, Canada and Australia to help protect against invasive meningococcal disease caused by serogroup B. Novartis plans to file for U.S. licensure of Bexsero as early as Q2; exact timing will depend on guidance from the FDA. This is the fourth Breakthrough Therapy designation for Novartis, underscoring leadership in developing innovative therapies and vaccines. This announcement comes on the heels of a landmark decision from regulators in the UK, where the Joint Committee on Vaccination and Immunisation recommended the inclusion of Bexsero in the country's National Immunisation Programme for routine use in infants from two months of age.
April 4, 2014
13:12 EDTMOSCanpotex announces agreement with Indian customers
Canpotex announced that it has agreed to an annual contract with its government and private sector partners in India to supply approximately 1 million tonnes of potash at a price of $322.00 per tonne on a CFR basis. Dechka also confirmed that Canpotex intends to expand its market development programs in India in future to help provide Indian farmers with the educational and other tools needed to improve yields through balanced fertilization and best management practices. Canpotex is the exclusive offshore marketing company owned by the three Saskatchewan potash producing companies: Agrium (AGU), Mosaic (MOS), and Potash Corporation of Saskatchewan (POT).
07:51 EDTADMArcher Daniels price target raised to $50 from $45 at Citigroup
Citigroup raised its price target for Archer Daniels shares to $50 after meeting with management and keeps a Buy rating on the stock. Citi said it has increased conviction that ADM's main businesses are building positive momentum.
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use